Key result
Plasma Siglec-5 and CD163 levels were negatively correlated with ejection fraction and demonstrated outstanding diagnostic performance for fulminant myocarditis.
Why the study?
Fulminant myocarditis is the severest type of myocarditis requiring timely diagnosis and treatment, but effective biomarkers for its early diagnosis are limited.
Do plasma Siglec-5 and CD163 levels serve as effective biomarkers for the early diagnosis of fulminant myocarditis?
Observational
Do plasma Siglec-5 and CD163 levels serve as effective biomarkers for the early diagnosis of fulminant myocarditis?
Plasma Siglec-5 and CD163 are identified as novel, valuable biomarkers for the early diagnosis and severity assessment of fulminant myocarditis.
May support biomarker evaluation in fulminant myocarditis; leaves open prospective validation before clinical adoption.
Fulminant myocarditis (FM) is the severest type of myocarditis and requires timely diagnosis and treatment. However, effective biomarkers for early diagnosis of FM are limited. First, 12 common inflammatory cytokines levels in the plasma of patients with FM were measured using human cytokine 12-Plex assay. Then, enzyme-linked immunosorbent assay (ELISA) was used to detect the plasma levels of another eight cytokines that we previously reported on. Moreover, a Spearman correlation test was employed to investigate the correlations between the plasma cytokine levels and the clinical parameters of patients with FM. Finally, receiver operating characteristic (ROC) curve analyses were performed to assess the diagnostic performance of plasma cytokine levels for the detection of FM. Five of the twelve common inflammation cytokines were significantly altered in patients with FM, but none of them was correlated with the severity of FM. Six of the eight significantly changed cytokines that we previously reported on were validated by ELISA. Among these, sST2, Siglec-5, and CD163 were negatively correlated with ejection fraction values. Furthermore, plasma Siglec-5 and CD163 levels were found to be associated with the severity of FM. Finally, both plasma Siglec-5 and CD163 showed outstanding diagnostic performance for FM. The current study identified plasma Siglec-5 and CD163 as valuable novel biomarkers for the early diagnosis of FM.
No takes yet. Share an insight, caveat, or question.
Zhuang et al. (2022) conducted an observational in Fulminant myocarditis. Plasma Siglec-5 and CD163 was evaluated on Diagnostic performance for fulminant myocarditis and correlation with severity. Plasma Siglec-5 and CD163 levels were negatively correlated with ejection fraction and demonstrated outstanding diagnostic performance for fulminant myocarditis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: